In the future, co-targeting CAIX/XII activity in combination with ferroptosis inducers, such as inhibitors of GPX4, have the potential to achieve substantial in-roads in treating hypoxic tumours, especially those exhibiting chemo- and radio-resistance. This evidence concerns the gene GPX4 and neoplasm.